Acute severe colitis: Infliximab and/or cyclosporine?

Mauro Fabro, Hajnalka Szabo, Giovanni Terrosu, Claudio Avellini, Maria Tabuso, Gionata Fiorino, Dario Sorrentino

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%. As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

Original languageEnglish
Pages (from-to)1448-1453
Number of pages6
JournalCurrent Drug Targets
Volume12
Issue number10
DOIs
Publication statusPublished - Sep 2011

Fingerprint

Colitis
Ulcerative Colitis
Cyclosporine
Surgery
Adrenal Cortex Hormones
Disease Management
Inflammatory Bowel Diseases
Monitoring
Hospitalization
Therapeutics
Mortality
Infliximab

Keywords

  • Colectomy
  • Corticosteroids
  • Cyclosporine
  • Infliximab
  • Severe colitis

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Fabro, M., Szabo, H., Terrosu, G., Avellini, C., Tabuso, M., Fiorino, G., & Sorrentino, D. (2011). Acute severe colitis: Infliximab and/or cyclosporine? Current Drug Targets, 12(10), 1448-1453. https://doi.org/10.2174/138945011796818234

Acute severe colitis : Infliximab and/or cyclosporine? / Fabro, Mauro; Szabo, Hajnalka; Terrosu, Giovanni; Avellini, Claudio; Tabuso, Maria; Fiorino, Gionata; Sorrentino, Dario.

In: Current Drug Targets, Vol. 12, No. 10, 09.2011, p. 1448-1453.

Research output: Contribution to journalArticle

Fabro, M, Szabo, H, Terrosu, G, Avellini, C, Tabuso, M, Fiorino, G & Sorrentino, D 2011, 'Acute severe colitis: Infliximab and/or cyclosporine?', Current Drug Targets, vol. 12, no. 10, pp. 1448-1453. https://doi.org/10.2174/138945011796818234
Fabro M, Szabo H, Terrosu G, Avellini C, Tabuso M, Fiorino G et al. Acute severe colitis: Infliximab and/or cyclosporine? Current Drug Targets. 2011 Sep;12(10):1448-1453. https://doi.org/10.2174/138945011796818234
Fabro, Mauro ; Szabo, Hajnalka ; Terrosu, Giovanni ; Avellini, Claudio ; Tabuso, Maria ; Fiorino, Gionata ; Sorrentino, Dario. / Acute severe colitis : Infliximab and/or cyclosporine?. In: Current Drug Targets. 2011 ; Vol. 12, No. 10. pp. 1448-1453.
@article{7e2da796e22243d5ae40fbd0dbfd4c0c,
title = "Acute severe colitis: Infliximab and/or cyclosporine?",
abstract = "Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1{\%}. As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.",
keywords = "Colectomy, Corticosteroids, Cyclosporine, Infliximab, Severe colitis",
author = "Mauro Fabro and Hajnalka Szabo and Giovanni Terrosu and Claudio Avellini and Maria Tabuso and Gionata Fiorino and Dario Sorrentino",
year = "2011",
month = "9",
doi = "10.2174/138945011796818234",
language = "English",
volume = "12",
pages = "1448--1453",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "10",

}

TY - JOUR

T1 - Acute severe colitis

T2 - Infliximab and/or cyclosporine?

AU - Fabro, Mauro

AU - Szabo, Hajnalka

AU - Terrosu, Giovanni

AU - Avellini, Claudio

AU - Tabuso, Maria

AU - Fiorino, Gionata

AU - Sorrentino, Dario

PY - 2011/9

Y1 - 2011/9

N2 - Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%. As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

AB - Acute severe ulcerative colitis is a serious condition that requires early hospitalization, with intensive monitoring and treatment. Despite the recent progress in the medical approach of Inflammatory Bowel Diseases acute severe ulcerative colitis remains a clinical challenge, with a mortality rate of nearly 1%. As of today, I.V. corticosteroids remain the 1st-line therapy for this complication. For non-responders (up to one-third of patients) possible options are surgery - whose timing is a critical point in the overall management of the disease - or rescue therapy with 2nd- line agents such as Cyclosporine and Infliximab. Here we will review the published studies dealing with the use of these medications in acute severe ulcerative colitis.

KW - Colectomy

KW - Corticosteroids

KW - Cyclosporine

KW - Infliximab

KW - Severe colitis

UR - http://www.scopus.com/inward/record.url?scp=80051699715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051699715&partnerID=8YFLogxK

U2 - 10.2174/138945011796818234

DO - 10.2174/138945011796818234

M3 - Article

C2 - 21466485

AN - SCOPUS:80051699715

VL - 12

SP - 1448

EP - 1453

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 10

ER -